News from Alkermes, ICON and NextPharma – People on the move
This week’s offering commences with news from Ireland-based Alkermes who has elected Nancy Wysenski to its Board of Directors.
Wysenski, recently serving as Chief Commercial Officer at Vertex Pharmaceutical, has over 35 years of healthcare experience.
Richard Pops, CEO of Alkermes, said: “Nancy’s exceptional grasp of the opportunities and challenges entailed in product launches, commercial development and operational growth will add significant strategic perspective as candidates from our pipeline portfolio.”
And click here to read about the company’s recent rejig of its Athlone, Ireland manufacturing facility.
Staying in Ireland and CRO ICON – who recently beat expectations with an unexpected uptick in revenue growth – has appointed Dr. Neil McCullough as Executive Vice President of Quality and Compliance and Corporate Training.
McCullough - who comes to ICON from PPD, and before that he worked for nine years at Pfizer - will provide strategic direction for quality management, quality assurance and corporate training across all ICON lines of business.
“Neil’s leadership and industry expertise will allow us to further enhance the quality and compliance solutions we offer to clients in support of their global drug development programmes,” said ICON CEO Ciaran Murray.
NextPharma next, and the contract manufacturer has announced the appointment of Jean Cuiné to its executive management team.
Cuiné comes to the company direct from Novartis where he held a number of senior roles in Chemistry Manufacturing and Controls (CMC) development.
Franck Latrille, CEO of NextPharma, said: “In this new role, Jean will be instrumental in driving forward our product development services on a global scale.”
And read here about how NextPharma is on the lookout for US acquisitions following the sale of Bioserv last year.
Over to QPharma now and Dr. Peter Shaw has been appointed Chief Medical Officer.
Shaw, who previously served as President and COO of MD Mindset, will oversee numerous initiatives, including QPharma’s QLaunch platform for maximizing the compliance and commercial effectiveness of life science product launches.
“Dr. Shaw’s breadth of experience as a physician, executive, and respected key opinion leader in the pharmaceutical industry speaks for itself,” said QPharma President and CEO Patrick P. Den Boer. “I am confident that he will bring outstanding value to our clients as a core member of our executive leadership team.”
Biohealth Innovation has appointed Ram Aiyar as its first Entrepreneur-in-Residence at the National Institutes of Health’s (NIH) National Heart, Lung and Blood Institute (NHLBI).
Aiyar will help advance fundamental research discoveries to new therapeutics, diagnostics and devices that can be used clinically and commercially.
Rich Bendis, Biohealth’s CEO welcomed Aiyar to the role, adding: “The growth of this program will be a benefit to BHI and our partner organizations for years to come, and will result in transitioning more early-stage biomedical technologies to commercial potential.”
